TGTX
$31.51
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Recent News
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)
TG Therapeutics Inc. (NASDAQ:TGTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 26, TG Therapeutics Inc. (NASDAQ:TGTX) reported Q4 revenue of $192.6 million compared with consensus estimates of $193.3 million. In a statement by their CEO, Michael Weiss, 2025 marked a good year for TG Therapeutics, […]
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance?
If you are wondering whether TG Therapeutics is attractively priced at its current level, this article will walk through what the numbers are really saying about the stock. The share price closed at US$29.27 recently, with returns of 1.4% over 30 days, a flat result year to date, and a 25.4% decline over the past year, set against a 94.4% gain over three years and a 39.1% decline over five years. These mixed returns have kept valuation questions front and center for many investors,...
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio
In early March 2026, Precision BioSciences announced it hit a clinical milestone under its license with TG Therapeutics for azercabtagene zapreleucel in progressive multiple sclerosis, triggering a US$7.5 million payment that combines US$5.25 million in cash and a US$2.25 million equity purchase, while TG separately reported strong 2025 revenue and earnings growth. The azer-cel milestone adds an emerging autoimmune cell therapy program alongside BRIUMVI, signalling that TG Therapeutics is...